A Phase 1 Study of Lenzilumab (KB003) in Subjects With Previously Treated Chronic Myelomonocytic Leukemia (CMML)

Trial Profile

A Phase 1 Study of Lenzilumab (KB003) in Subjects With Previously Treated Chronic Myelomonocytic Leukemia (CMML)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Lenzilumab (Primary)
  • Indications Chronic myelomonocytic leukaemia
  • Focus Adverse reactions
  • Sponsors Humanigen
  • Most Recent Events

    • 07 Aug 2017 According to Humanigen media release, KaloBios Pharmaceuticals changed its name to Humanigen.
    • 27 Jul 2017 According to a KaloBios Pharmaceuticals media release, the company plans the development of an interim analysis this phase 1 trial in Chronic Myelomonocytic Leukemia (CMML) in 2017.
    • 29 Nov 2016 According to a KaloBios Pharmaceuticals media release, the company plans to discuss interim data from the study at the 2016 Juvenile Myelomonocytic Leukemia (JMML) International Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top